Praxis Precision Medicines Inc
NASDAQ:PRAX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Praxis Precision Medicines Inc
NASDAQ:PRAX
|
US |
|
Olympic Steel Inc
NASDAQ:ZEUS
|
US |
|
M
|
Metrofile Holdings Ltd
JSE:MFL
|
ZA |
|
Confluent Inc
NASDAQ:CFLT
|
US |
|
D
|
Daikin Industries Ltd
OTC:DKILY
|
JP |
|
Resource Generation Ltd
ASX:RES
|
AU |
|
CHAPTERS Group AG
XETRA:CHG
|
DE |
|
Hengan International Group Company Ltd
OTC:HEGIY
|
CN |
Praxis Precision Medicines Inc
In the realm of biotechnology, Praxis Precision Medicines Inc. has emerged as a distinctive player, navigating the intricate path of neuropsychiatric and neurological disorder treatment. Founded with a mission to develop therapies that directly address the underlying causes of brain disorders, Praxis capitalizes on the integration of genetic insights and brain circuitry. This approach fuels the company’s innovative pipeline, which aims to launch first-in-class or best-in-class treatments for conditions often considered unmanageable or neglected. By leveraging deep genetic knowledge and pioneering circuit-based methodologies, Praxis concentrates its research on specific neural pathways in the hope of crafting target-specific drugs, thereby enhancing both efficacy and safety for patients.
Praxis Precision Medicines generates revenue primarily through the clinical development and eventual commercialization of its drug candidates. The company invests heavily in research and development, often funded by strategic partnerships, private investments, and public offerings. As Praxis advances its drug candidates through various phases of clinical trials, it also seeks to strike beneficial collaborations with larger pharmaceutical entities, thus securing upfront payments, milestone fees, and royalties. This business model allows Praxis to sustain its scientific endeavors while setting the stage for potential revenue streams, contingent upon the successful approval and market introduction of its innovative therapies. Through this cycle of rigorous R&D and strategic partnerships, Praxis aims to transform its cutting-edge research into tangible medical solutions, contributing to its growth and financial health.
In the realm of biotechnology, Praxis Precision Medicines Inc. has emerged as a distinctive player, navigating the intricate path of neuropsychiatric and neurological disorder treatment. Founded with a mission to develop therapies that directly address the underlying causes of brain disorders, Praxis capitalizes on the integration of genetic insights and brain circuitry. This approach fuels the company’s innovative pipeline, which aims to launch first-in-class or best-in-class treatments for conditions often considered unmanageable or neglected. By leveraging deep genetic knowledge and pioneering circuit-based methodologies, Praxis concentrates its research on specific neural pathways in the hope of crafting target-specific drugs, thereby enhancing both efficacy and safety for patients.
Praxis Precision Medicines generates revenue primarily through the clinical development and eventual commercialization of its drug candidates. The company invests heavily in research and development, often funded by strategic partnerships, private investments, and public offerings. As Praxis advances its drug candidates through various phases of clinical trials, it also seeks to strike beneficial collaborations with larger pharmaceutical entities, thus securing upfront payments, milestone fees, and royalties. This business model allows Praxis to sustain its scientific endeavors while setting the stage for potential revenue streams, contingent upon the successful approval and market introduction of its innovative therapies. Through this cycle of rigorous R&D and strategic partnerships, Praxis aims to transform its cutting-edge research into tangible medical solutions, contributing to its growth and financial health.
NDA Submissions: Praxis submitted two New Drug Applications (NDAs): one for ulixacaltamide in essential tremor and another for relutrigine in SCN2A and 8A developmental and epileptic encephalopathies (DEEs).
Clinical Achievements: 2025 was described as a remarkable year, with positive readouts and regulatory advances across ulixacaltamide, relutrigine, vormatrigine, and elsunersen.
Upcoming Data: Key topline results expected in Q2 include POWER1 for vormatrigine in focal epilepsy and Part A of the EMBRAVE study for elsunersen.
Strong Cash Position: Praxis ended Q4 with $926 million in cash and raised an additional $621 million in January, resulting in pro forma cash of approximately $1.5 billion to fund operations into 2028.
Commercial Preparation: The company is actively hiring, building inventory, and focusing on disease awareness campaigns ahead of anticipated launches.
Market Opportunity: Management estimates annual revenue potential at over $10 billion for ulixacaltamide, $5 billion for relutrigine, $4 billion for vormatrigine, and $1 billion for elsunersen.
No Priority Review for Ulixacaltamide: Praxis chose standard review for ulixacaltamide for strategic business reasons, including market timing and maximizing value given IRA considerations.
Operating Expenses Rise: Operating expenses increased substantially year-over-year, driven by portfolio progress and preparation for commercialization.
